Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY26 results · Jan–Mar 2026
Solara Active Pharma Sciences reported revenue from operations of ₹387.29 crore (up 41.9% from Q4 FY25) and net profit of ₹9.60 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 387.29 | 273.01 | +41.9% | 349.00 | +11.0% |
| Other income | 4.69 | 5.95 | −21.2% | 0.00 | — |
| Total income | 391.98 | 278.96 | +40.5% | 349.00 | +12.3% |
| Profit before tax | 9.60 | (2.10) | Turned profit | (17.43) | Turned profit |
| Net profit for the period | 9.60 | (2.10) | Turned profit | (17.43) | Turned profit |
| EPS, basic (₹) | 2.20 | (0.93) | not comparable | (3.98) | Turned profit |
| Net margin (%) | 2.5 | -0.8 | -5.0 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 387.29 | 273.01 | +41.9% | 349.00 | +11.0% |
| Other income | 4.42 | 5.95 | −25.7% | 0.00 | — |
| Total income | 391.71 | 278.96 | +40.4% | 349.00 | +12.2% |
| Profit before tax | 9.73 | (4.88) | Turned profit | (17.42) | Turned profit |
| Net profit for the period | 9.73 | (4.88) | Turned profit | (17.42) | Turned profit |
| EPS, basic (₹) | 2.23 | (1.65) | not comparable | (3.97) | Turned profit |
| Net margin (%) | 2.5 | -1.8 | -5.0 |
Consolidated
- Filed with BSE
- 15 May 2026, 19:28 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 May 2026, 19:28 IST
- Board meeting
- 15 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE